Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2877 - The impact of completeness of chemotherapy on the efficacy of irinotecan in the preoperative chemoradiotherapy of locally advanced rectal cancer.


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Jingwen Wang


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


J. Wang1, J. Fan2, C. Li2, L. Shen2, L. Yang2, F. Xia2, J. Wan2, Z. Zhang2, J. Zhu1

Author affiliations

  • 1 Department Of Radiation Oncology, Fudan Univerisity Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Department Of Radiation Oncology, Fudan Univeristy Shanghai Cancer Center, 200032 - Shanghai/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2877


The purpose of this study was to explore the impact of completeness of weekly irinotecan combined with capecitabine-based preoperative chemoradiotherapy in patients with locally advanced rectal cancer (LARC).


LARC patients receiving neoadjuvant CRT between May 2011 and February 2018 were enrolled. The paradigm included preoperative pelvic RT (50 Gy/25Fx) concurrently with capecitabine (625 mg/m2, bid, d1-5) and irinotecan (80 mg/m2 for UGT1A1*1*1 genotype or 65 mg/m2 for UGT1A1*1*28 genotype, qw), followed by a course of XELIRI and surgery. The actual cycles of concurrent irinotecan delivered was reviewed from the electronic records. Patients were divided into the low-completeness group (1∼3 cycles) and the high-completeness group (4∼5 cycles). Univariate and multivariate analyses were performed to identify risk factors of the completeness. A nomogram was built to divide patients into 3 groups with different risk.


A total of 371 patients were enrolled, with 102 patients from a phase III clinical trial (CinClare, NCT02605265). The proportion of patients with low completeness was 32.4% versus 67.6% with high completeness in the CinClare group, and 41.3% versus 58.7% in the remaining group (p = 0.12). In the CinClare group, the complete response (CR) rate was 24.2% in the low-completeness patients versus 42.6% in the high-completeness patients (p = 0.07). The difference was more significant in the general population (28.6% vs 71.6%, p = 0.02). Univariate analysis showed age over 60, female, anemia at baseline, and a low pretreatment pre-Alb level were associated with a low completeness. By using multivariate analysis and building a nomogram, we could divide patients into 3 groups: (1) high-risk group (risk score>200); (2) intermediate-risk group (score 100∼200); (3) low-risk group (score≤100). The rates of high completeness in the 3 groups were 27.8%, 47.6% and 69.5%, respectively.


Our analysis suggested a higher completeness of weekly irinotecan was associated with a higher CR rate. Comprehensive evaluation of the patient performance is necessary before starting the intensified treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.